179 related articles for article (PubMed ID: 36892593)
61. Clinical significance of minimal residual disease in young adults with standard-risk/Ph-negative precursor B-acute lymphoblastic leukemia: results of prospective study.
Salah-Eldin M; Abousamra NK; Azzam H
Med Oncol; 2014 May; 31(5):938. PubMed ID: 24692146
[TBL] [Abstract][Full Text] [Related]
62. [Retrospective Analysis of the Impact of Treatment on Prognosis in 44 Adolescents and Young Adult Patients with Acute Lymphoblastic Leukemia].
Chen XP; Lv N; Li YH; Jing Y; Yu L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Feb; 24(1):14-8. PubMed ID: 26913386
[TBL] [Abstract][Full Text] [Related]
63. Philadelphia-like acute lymphoblastic leukemia is associated with minimal residual disease persistence and poor outcome. First report of the minimal residual disease-oriented GIMEMA LAL1913.
Chiaretti S; Messina M; Della Starza I; Piciocchi A; Cafforio L; Cavalli M; Taherinasab A; Ansuinelli M; Elia L; Albertini Petroni G; La Starza R; Canichella M; Lauretti A; Puzzolo MC; Pierini V; Santoro A; Spinelli O; Apicella V; Capria S; Di Raimondo F; De Fabritiis P; Papayannidis C; Candoni A; Cairoli R; Cerrano M; Fracchiolla N; Mattei D; Cattaneo C; Vitale A; Crea E; Fazi P; Mecucci C; Rambaldi A; Guarini A; Bassan R; Foà R
Haematologica; 2021 Jun; 106(6):1559-1568. PubMed ID: 32467145
[TBL] [Abstract][Full Text] [Related]
64. Improved survival in adolescents and young adults (AYA) patients aged 14-55 years with acute lymphoblastic leukemia using pediatric-inspired protocol - a retrospective analysis of a real-world experience in 79 of patients treated at a national tertiary care referral center.
Hanbali A; Kotb A; Fakih RE; Alfraih F; Ahmed SO; Shaheen M; Alhayli S; Alahmari A; Alotaibi A; Alshaibani A; Riash MA; Deeba F; Asif M; Rasheed W; Alzahrani H; Alsharif F; Chaudhri N; Almohareb F; Aljurf M
Leuk Res Rep; 2021; 16():100270. PubMed ID: 34631407
[TBL] [Abstract][Full Text] [Related]
65. Treatment of adult patients with acute lymphoblastic leukemia in the Czech Republic in the period 2007-2020.
Šálek C; Hrabovský Š; Folber F; Horáček JM; Kořístek Z; Szotkowski T; Pecherková P; Froňková E; Doubek M; Leukemická Skupina-Pro Život Cell Č
Klin Onkol; 2023; 36(4):382-395. PubMed ID: 37877531
[TBL] [Abstract][Full Text] [Related]
66. Outcome of children with newly diagnosed acute lymphoblastic leukemia treated with CCLG-ALL 2008: The first nation-wide prospective multicenter study in China.
Cui L; Li ZG; Chai YH; Yu J; Gao J; Zhu XF; Jin RM; Shi XD; Zhang LP; Gao YJ; Zhang RD; Zheng HY; Hu SY; Cui YH; Zhu YP; Zou Y; Ng MHL; Xiao Y; Li JH; Zhang YH; He HL; Xian Y; Wang TY; Li CK; Wu MY;
Am J Hematol; 2018 Jul; 93(7):913-920. PubMed ID: 29675840
[TBL] [Abstract][Full Text] [Related]
67. Influence of Minimal Residual Disease at Day 15 of Induction Therapy on Survival of Children with Acute Lymphoblastic Leukemia.
Samardžić-Predojević J; Đurđević-Banjac B; Malčić-Zanić D
Acta Med Acad; 2023 Dec; 52(3):153-160. PubMed ID: 38407081
[TBL] [Abstract][Full Text] [Related]
68. Assessment of Minimal Residual Disease in Childhood Acute Lymphoblastic Leukemia: A Multicenter Study From Turkey.
Tüfekçi Ö; Evim MS; Güneş AM; Celkan T; Karapinar DY; Kaya Z; Baysal B; Baytan B; Koçak Ü; Yilmaz Ş; Çinar S; Ören H
J Pediatr Hematol Oncol; 2022 Mar; 44(2):e396-e402. PubMed ID: 35129146
[TBL] [Abstract][Full Text] [Related]
69. Minimal residual disease in adolescent (older than 14 years) and adult acute lymphoblastic leukemias: early immunophenotypic evaluation has high clinical value.
Vidriales MB; Pérez JJ; López-Berges MC; Gutiérrez N; Ciudad J; Lucio P; Vazquez L; García-Sanz R; del Cañizo MC; Fernández-Calvo J; Ramos F; Rodríguez MJ; Calmuntia MJ; Porwith A; Orfao A; San-Miguel JF
Blood; 2003 Jun; 101(12):4695-700. PubMed ID: 12586618
[TBL] [Abstract][Full Text] [Related]
70. Retrospective study of Dana Farber Consortium Protocol in newly diagnosed Egyptian adolescents and young adults with acute lymphoblastic leukemia: Tanta experience.
Elashtokhy HEA; Elgohary HE; Eldeep BB; Gaber SM; Elbedewy TA
J Egypt Natl Canc Inst; 2021 Apr; 33(1):9. PubMed ID: 33826046
[TBL] [Abstract][Full Text] [Related]
71. Association of minimal residual disease with clinical outcomes in Philadelphia chromosome positive acute lymphoblastic leukemia in the tyrosine kinase inhibitor era: A systemic literature review and meta-analysis.
Zhang W; Jang E
PLoS One; 2021; 16(8):e0256801. PubMed ID: 34437635
[TBL] [Abstract][Full Text] [Related]
72. Minimal residual disease (MRD) analysis in the non-MRD-based ALL IC-BFM 2002 protocol for childhood ALL: is it possible to avoid MRD testing?
Fronkova E; Mejstrikova E; Avigad S; Chik KW; Castillo L; Manor S; Reznickova L; Valova T; Zdrahalova K; Hrusak O; Jabali Y; Schrappe M; Conter V; Izraeli S; Li CK; Stark B; Stary J; Trka J
Leukemia; 2008 May; 22(5):989-97. PubMed ID: 18305563
[TBL] [Abstract][Full Text] [Related]
73. Description and prognostic significance of the kinetics of minimal residual disease status in adults with acute lymphoblastic leukemia treated with HyperCVAD.
Cassaday RD; Stevenson PA; Wood BL; Becker PS; Hendrie PC; Sandmaier BM; Radich JL; Shustov AR
Am J Hematol; 2018 Aug; 93(4):546-552. PubMed ID: 29318644
[TBL] [Abstract][Full Text] [Related]
74. The prognostic significance of minimal residual disease in adult Egyptian patients with precursor acute lymphoblastic leukemia.
Samra MA; Mahmoud HK; Abdelhamid TM; El Sharkawy NM; Elnahass YH; Elgammal M; Abdelfattah RM; Eid S; Ghaleb FM; Kamel AM
J Egypt Natl Canc Inst; 2013 Sep; 25(3):135-42. PubMed ID: 23932750
[TBL] [Abstract][Full Text] [Related]
75. Pediatric patients with acute lymphoblastic leukemia treated with blinatumomab in a real-world setting: Results from the NEUF study.
Locatelli F; Maschan A; Boissel N; Strocchio L; Alam N; Pezzani I; Brescianini A; Kreuzbauer G; Baruchel A
Pediatr Blood Cancer; 2022 Apr; 69(4):e29562. PubMed ID: 35044079
[TBL] [Abstract][Full Text] [Related]
76. Impact of tyrosine kinase inhibitors on minimal residual disease and outcome in childhood Philadelphia chromosome-positive acute lymphoblastic leukemia.
Jeha S; Coustan-Smith E; Pei D; Sandlund JT; Rubnitz JE; Howard SC; Inaba H; Bhojwani D; Metzger ML; Cheng C; Choi JK; Jacobsen J; Shurtleff SA; Raimondi S; Ribeiro RC; Pui CH; Campana D
Cancer; 2014 May; 120(10):1514-9. PubMed ID: 24501014
[TBL] [Abstract][Full Text] [Related]
77. Childhood high-risk acute lymphoblastic leukemia in first remission: results after chemotherapy or transplant from the AIEOP ALL 2000 study.
Conter V; Valsecchi MG; Parasole R; Putti MC; Locatelli F; Barisone E; Lo Nigro L; Santoro N; Aricò M; Ziino O; Pession A; Testi AM; Micalizzi C; Casale F; Zecca M; Casazza G; Tamaro P; La Barba G; Notarangelo LD; Silvestri D; Colombini A; Rizzari C; Biondi A; Masera G; Basso G
Blood; 2014 Mar; 123(10):1470-8. PubMed ID: 24415536
[TBL] [Abstract][Full Text] [Related]
78. Early MRD response as a prognostic factor in adult patients with acute lymphoblastic leukemia.
Šálek C; Folber F; Froňková E; Procházka B; Marinov I; Cetkovský P; Mayer J; Doubek M;
Eur J Haematol; 2016 Mar; 96(3):276-84. PubMed ID: 25997106
[TBL] [Abstract][Full Text] [Related]
79. Refining risk classification in childhood B acute lymphoblastic leukemia: results of DFCI ALL Consortium Protocol 05-001.
Vrooman LM; Blonquist TM; Harris MH; Stevenson KE; Place AE; Hunt SK; O'Brien JE; Asselin BL; Athale UH; Clavell LA; Cole PD; Kelly KM; Laverdiere C; Leclerc JM; Michon B; Schorin MA; Sulis ML; Welch JJG; Neuberg DS; Sallan SE; Silverman LB
Blood Adv; 2018 Jun; 2(12):1449-1458. PubMed ID: 29941458
[TBL] [Abstract][Full Text] [Related]
80. [Clinical significance of dynamic monitoring the minimal residual disease in childhood B-lineage acute lymphoblastic leukemia by multiparameter flow cytometry].
Guo DD; Zhao WL; Zhang YL; Pang L; Che L; He HL; Chai YH; Ji ZH; Ji XQ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Dec; 20(6):1346-51. PubMed ID: 23257430
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
